GlassScriptPhysician profile
Matthew A Beldner
NPI 1760570675
$9,169.78
in general payments reported to CMS, 2019-2025
69 companies · $3,685 in 2025
The $3,685 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $314 · 2021: $233 · 2022: $364 · 2023: $1,380 · 2024: $2,680 · 2025: $3,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,575 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,575.26 |
| Education | $169.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $881.83 | 2019-2025 | |
| Janssen Biotech, INC. | $577.07 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Merck Sharp & Dohme LLC | $554.12 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $546.10 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $531.63 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Pfizer INC. | $419.43 | 2020-2025 | |
| Abbvie INC. | $389.51 | 2020-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $385.20 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Gilead Sciences, INC. | $355.86 | 2021-2025 | Trodelvy |
| Lilly USA, LLC | $271.54 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Rigel Pharmaceuticals, INC. | $237.62 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genzyme Corporation | $221.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $203.14 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $188.95 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $175.05 | 2020-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $173.13 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $138.34 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Jazz Pharmaceuticals INC. | $131.83 | 2024-2025 | |
| Pharmaessentia USA Corporation | $118.88 | 2024-2025 | Besremi |
| Taiho Oncology, INC. | $116.11 | 2024-2025 | |
| Puma Biotechnology, INC. | $113.58 | 2022-2025 | |
| Incyte Corporation | $110.69 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Servier Pharmaceuticals LLC | $102.12 | 2024-2025 | |
| Celgene Corporation | $99.94 | 2019-2025 | Reblozyl |
| Adaptive Biotechnologies Corporation | $97.83 | 2022-2025 | Clonoseq |
| Beigene USA, INC. | $95.96 | 2022-2025 | Brukinsa |
| Menarini Silicon Biosystems, INC. | $94.85 | 2023 | Cellsearch |
| Deciphera Pharmaceuticals INC. | $90.80 | 2023-2024 | Qinlock |
| Sobi, INC | $89.14 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $83.10 | 2019-2025 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $81.96 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Alnylam Pharmaceuticals INC. | $81.26 | 2022-2025 | Givlaari |
| Emd Serono, INC. | $78.00 | 2021-2025 | Bavencio |
| Stemline Therapeutics INC. | $73.12 | 2023-2025 | Orserdu |
| Amgen INC. | $71.24 | 2019-2023 | Kyprolis, Blincyto |
| Adc Therapeutics America, INC. | $69.92 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.45 | 2024-2025 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $58.16 | 2024-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $54.93 | 2023-2025 | Fotivda |
| Kite Pharma, INC. | $52.73 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $51.67 | 2020-2025 | Xpovio |
| Cumberland Pharmaceuticals, INC. | $49.02 | 2023-2025 | Sancuso |
| Beone Medicines USA, INC. | $48.85 | 2025 | Brukinsa |
| Tempus Ai, INC | $48.24 | 2024-2025 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $47.12 | 2024 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $46.94 | 2019 | |
| Fresenius Kabi USA, LLC | $46.56 | 2025 | Stimufend |
| Astellas Pharma US INC | $45.65 | 2023-2025 | Vyloy, Padcev |
| Shield Therapeutics INC | $43.89 | 2024-2025 | |
| Seagen INC. | $43.08 | 2019-2023 | Adcetris |
| Medtronic, INC. | $40.08 | 2023 | Osteocool Rf Ablation System |
| Acrotech Biopharma INC. | $34.17 | 2023 | Beleodaq |
| Dendreon Pharmaceuticals LLC | $33.99 | 2025 | Provenge |
| Mirati Therapeutics, INC. | $32.30 | 2023-2024 | Krazati |
| Caris Mpi, INC. | $24.32 | 2025 | Mi Cancer Seek |
| Pharmaand Gmbh | $23.53 | 2025 | Rubraca |
| Tolmar, INC. | $23.53 | 2025 | Eligard, Rubraca |
| Coherus Oncology, INC. | $23.42 | 2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $22.01 | 2024 | Cosela |
| Kyowa Kirin, INC. | $21.98 | 2019 | |
| Immunocore Limited | $21.43 | 2025 | Kimmtrak |
| Cycle Pharmaceuticals INC | $21.19 | 2025 | Phyrago |
| Recordati_rare_diseases_inc. | $19.42 | 2025 | Enjaymo |
| Sumitomo Pharma America, INC. | $17.58 | 2024 | Orgovyx |
| Eisai INC. | $15.67 | 2020 | |
| Springworks Therapeutics, INC. | $14.62 | 2025 | Gomekli |
| Tesaro, INC. | $11.96 | 2019 | |
| Exelixis INC. | $11.57 | 2019 | |
| Mylan Institutional INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Beldner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.